Evaluation of the pharmacokinetic interaction between candesartan cilexetil and felodipine

Journal of Bioequivalence and Bioavailability

Volumn 3, Issue 1, 2011, Pages 005-010

  Junior, Eduardo Abib ^a,b   Duarte, Luciana Fernandes ^b   Oliveira, Luciana ^c   Barros, Fabio Proença ^d  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Scentryphar Clinical Research   (Brazil)

^c ASTRAZENECA   (United Kingdom)

^d Core Clinical Research ^*  (Brazil)

Author keywords

Bioequivalence; Biological availability; Candesartan; Chromatography; Felodipine; Pharmacokinetics

Indexed keywords

CANDESARTAN; CANDESARTAN HEXETIL; FELODIPINE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY;

EID: 79952340080     PISSN: None     EISSN: 09750851     Source Type: Journal    
DOI: 10.4172/jbb.1000049     Document Type: Article

References (53)

1. ® and antihypertensive effect of conventional and extended release felodipine tablets. Br J Clin Pharmacol 29: 39-45.
2. Blychert E, Edgar B, Elmfeldt D, Hedner T (1991) A population study of the pharmacokinetics of felodipine. Blood Press 31: 15-24.
3. Blychert E (1992) Felodipine pharmacokinetics and plasma concentration vs effect relationships. Blood Press 2: 1-30.
4. Dahlöf B, Andersson OK (1995) A felodipine-metoprolol extended-release tablet: Its properties and clinical development. J Hum Hypertens 9: 43-47.
5. Dunselman PH, Edgar B (1991) Felodipine clinical pharmacokinetics. Clin Pharmacokinet 21: 418-430.
6. Edgar B, Regardh C, Lundborg G, Romare PS, Nyberg G (1987) Pharmacokinetics and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. Biopharm. Drug Dispos 8: 235-248.
7. Eriksson M, Nyberg G, Lidman K (1993) Aiming for steady 24-hour plasma concentrations: A comparison of two calcium antagonist and beta-blocker combinations. Blood Press Suppl 1: 16-21.
8. Gleiter CH, Morike KE (2002) Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 41: 07-17.
9. Gradman AH, Lewin A, Bowling BT (1999) For the Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Heart Dis 1: 52-57.
10. Hallin L, Andren L, Hansson L (1983) Controlled trial of nifedipine and bendroflumethiazide in hypertension. J Cardiovasc Pharmacol 5: 1083-1085.
11. Hansson L, Zanchetti A, Carruthers SG (1998) Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351: 1755-1762.
12. Hedner T, Sjogren E, Elmfeldt D (1987) Antihypertensive effects and pharmacokinetics of felodipine combined with a,-blocker and, a diuretic. J Cardiovasc Pharmac 10: 177-184.
13. Ikechi GO, Brian LR (2010) Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction. Integrated Blood Pressure Control 3: 45-55.
14. Kloner RA, Weinberger M, Pool JL (2001) For the Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol 87: 727-731.
15. Little WC, Cheng CP, Elvelin L (1995) Vascular selective calcium entry blockers in the treatment of cardiovascuolar disorders: focus on felodipine. Cardiovasc. Drugs Ther 9: 657-663.
16. MacCarthy EP (1987) Dihydropyridines and beta-adrenoceptor antagonists as combination treatment in hypertension. J Hypertens 5: 133-137.
17. MacConnachie AM, Maclean D (1995) Low dose combination antihypertensive therapy: Additional efficacy without additional adverse effects. Drug Saf 12: 85-90.
18. Mann SJ, Gerber LM (2001) Low-dose alpha/beta blockade in the treatment of essential hypertension. Am J Hypertens 14: 553-558.
19. Matheson AJ, Cheer SM, Goa KL (2001) Perindopril/indapamide 2/0.625 mg/ day: A review of its place in the management of hypertension. Drugs 61: 1211-1229.
20. McFayden RJ, Reid JL (1994) Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens 12: 1333-1338.
21. Melian EB, Jarvis B (2002) Candesartan cilexetil plus hydrochlorothiazide combination: A review of its use in hypertension. Drugs 62: 787-816.
22. Messerli FH (1992) Combination therapy in hypertension. J HumHypertens 6: 19-21.
23. Messerli FH, Chander K (2000) Cardiac effects of combination therapy in hypertension. J Cardiovasc Pharmacol 35: 17-22.
24. Michalewicz L, Messerli FH (1997) Cardiac effects of calcium antagonists in systemic hypertension. Am J Cardiol 79: 39-46.
25. Morgan T, Anderson AA (2002) Comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 15: 544-549.
26. Morimoto S, Ogibara T (1994) TCV-116: A new angiotensin n type-1 receptor antagonist. Cardiovasc Drug Rev 12: 153-164.
27. Muller JE (1999) Circadian variation in cardiovascular events. AM J Hypertens 12: 35-42.
28. Nalbantgil I, Önder R, Kiliccioglu B, Turkoglu C (1993) Combination therapy with verapamil and nitrendipine in patients with hypertension. J Hum Hypertens 7: 305-308.
29. Nalbantgil I, Önder R, Nalbantgil S (1996) Sustained-release verapamil and trandolapril, alone and in combination, in the treatment of obese hypertensive patients: A double-blind pilot study. Curr Ther Res Clin Exp 57: 990-997.
30. Nalbantgil S, Nalbantgil I, Önder R (2000) Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. Am J Hypertens 13: 921-926.
31. Neutel JM (1999) Low-dose antihypertensive combination therapy: Its rationale and role in cardiovascular risk management. Am J Hypertens 12: 73-79.
32. Nishikawa K, Naka T, Chatani F, Yoshimura Y (1997) Candesartan cilexetil: A review of its preclinical pharmacology. J Human Hypertens 11: 9-17.
33. O'Brien ET, MacKinnon J (1972) Propranolol and polythiazide in the treatment of hypertension. Br Heart J 34: 1042-1044.
34. Oparil S, Levine JH, Zuschke CA (1999) For the Candesartan Cilexetil Study Investigators. Effect of candesartan cilexetil in patients with severe systemic hypertension. Am J Cardiol 84: 289-293.
35. Opie LH, Messerli FH (2001) The choice of first-line therapy: Rationale for low-dose combinations of an angiotensin converting enzyme inhibitor and a diuretic. J Hypertens Suppl 19: 17-21.
36. Philipp T, Letzel H, Arens HJ (1997) Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 11: 67-68.
37. Plouin PF (1997) Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Hum Hypertens 11: 65-66.
38. Prichard BN (1984) Combined alpha and beta receptor inhibition in the treatment of hypertension. Drugs 28: 51-68.
39. Roca-Cusachs A, Torres F, Horas M (2001) Nitrendipine and enalapril combination therapy in mild to moderate hypertension: Assessment of doseresponse relationship by a clinical trial of factorial design. J Cardiovasc Pharmacol 38: 840-849.
40. Saltiel E, Ellrodt AG, Monk JP (1988) A Review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 36: 387-428.
41. Sanem N, Mehdi Z, Filiz O, Bahar B, Istemi N, Remzi O, Mustafa A (2003) Comparison of Candesartan and Felodipine Alone and Combined in the Treatment of Hypertension: A Single-Center, Double-Blind, Randomized, Crossover Trial. Current Therapeutic Research 64: 380-388.
42. Schulman DS, Flores AR, Tugoen J (1996) Antihypertensive treatment in hypertensive patients with normal left ventricular remodeling and improved diastolic function. Am J Cardiol 78: 56-60.
43. Sever PS, Poulter NR (1987) Calcium antagonists and diuretics as combined therapy. J Hypertens Suppl 5: 123-126.
44. Shibouta Y (1993) Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-l-[[2'-(lH-tetrazol-5-yl]biphenyl-4-yl]methyl]- lH-benzimidazoie-7-carboxylic acid (CV-11974) and its prodrug, (+)-l-(cyciohexyioxycarbonyloxy)-ethyl-2-ethoxy-l-[[2'(lH-tetrazol5yl)biphenyl-4-yl]-methyl]-lH-benzimidazole-7-carboxylate (TCV-116]. Pharmacol Exp Ther 266: 114-120.
45. Siegl PKS, Kivlighn SD, Broten TP (1994) Pharmacology of angiotensin II receptor antagonists: Comparison with renin inhibitors and angiotensinconverting enzyme inhibitors. Expert Opin Invest Drugs 3: 925-944.
46. Sleight P (1994) Cardiac benefits of ACE inhibitors and calcium antagonists alone and in combination. J Cardiovasc Pharmacol 23: 39-42.
47. Song H, Bao W, Wang H, An G, Feny J, Wang R, Zhang Y, An F (2008) Effects of extended release felodipine on endothelial vasoactive substances in patients with essential hypertension. Clin Chem Lab Med 46: 393-395.
48. Timmermans PB, Wong PC, Chiu AT (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251.
49. Walton T, Symes LR (1993) Felodipine and isradipine: new calcium-channelblocking agents for the treatment of hypertension. Clin Pharm 12: 261-275.
50. Weir MR (1998) The rationale for combination versus single-entity therapy in hypertension. Am J Hypertens 11: 163-169.
51. Wingstrand K, Abrahamsson B, Edgar B (1990) Bioavailability from felodipine extended release tablets with deferent dissolution properties. Int J Pharm 60: 151-156.
52. Yao R, Cheng X, Liao YH (2008) Molecular mechanisms of felodipine suppressing atheroscelerosis in high-cholesteroldiet apolipoprotein E-knockout mice. J Cardiovasc Pharmacol 51: 188-195.
53. Yedinak KC, Lopez LM (1991) Felodipine: a new dihydropyridine calcium channel antagonist. DICP 25: 1193-1206.